Literature DB >> 21855538

Elevated systemic monocyte chemoattractrant protein-1 in hepatic steatosis without significant hepatic inflammation.

Georgi Kirovski1, Christoph Dorn, Hanna Huber, Lukas Moleda, Catrin Niessen, Hella Wobser, Doris Schacherer, Christa Buechler, Reiner Wiest, Claus Hellerbrand.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is strongly associated with obesity and the metabolic syndrome. It encompasses a clinico-pathologic spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). The latter develops upon pro-inflammatory cell infiltration and is widely considered as the first relevant pathophysiological step in NAFLD-progression. The chemokine monocyte chemoattractant protein 1 (MCP-1) plays an important role in the progression of hepatic inflammation and fibrosis, and both increased hepatic expression and circulating serum levels have been described in NASH. Here, we aimed to investigate MCP-1 expression in simple hepatic steatosis. Upon feeding a high-fat diet mice developed hepatic steatosis in the absence of significant hepatic inflammation, but elevated hepatic MCP-1 expression compared to control mice fed a standard chow. Interestingly, high-fat diet fed mice had significantly higher MCP-1 serum levels, and MCP-1 mRNA expression was significantly increased in visceral adipose tissue. Furthermore, MCP-1 serum levels were also elevated in patients with ultrasound-diagnosed NAFLD and correlated with the body-mass index and fasting glucose. In conclusion, our data indicate both the liver and adipose tissue as cellular sources of elevated circulating MCP-1 levels already in the early phase of hepatic steatosis. Since MCP-1 derived from visceral adipose tissue reaches the liver via portal circulation at high concentrations it may significantly contribute to the progression of simple steatosis to NASH.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21855538     DOI: 10.1016/j.yexmp.2011.08.001

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  9 in total

Review 1.  Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.

Authors:  Jun Wei Lim; John Dillon; Michael Miller
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 2.  Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.

Authors:  Kareem Hassan; Varun Bhalla; Mohammed Ezz El Regal; H Hesham A-Kader
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

3.  CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease.

Authors:  Richard Parker; Christopher J Weston; Zhenhua Miao; Christopher Corbett; Matthew J Armstrong; Linda Ertl; Karen Ebsworth; Matthew J Walters; Trageen Baumart; Dale Newland; Jeff McMahon; Penglie Zhang; Rajinder Singh; James Campbell; Philip N Newsome; Israel Charo; Thomas J Schall; David H Adams
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-02-08       Impact factor: 4.052

4.  A "Western Diet" promotes symptoms of hepatic steatosis in spontaneously hypertensive rats.

Authors:  Siân P Cartland; Nicole Tamer; Manisha S Patil; Belinda A Di Bartolo; Mary M Kavurma
Journal:  Int J Exp Pathol       Date:  2020-08-12       Impact factor: 1.925

5.  Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Oliver Glass; Ricardo Henao; Keyur Patel; Cynthia D Guy; Hans J Gruss; Wing-Kin Syn; Cynthia A Moylan; Robert Streilein; Russell Hall; Anna Mae Diehl; Manal F Abdelmalek
Journal:  Hepatol Commun       Date:  2018-09-21

6.  miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling.

Authors:  Hossein Sendi; Ivy Mead; Meimei Wan; Marjan Mehrab-Mohseni; Kenneth Koch; Anthony Atala; Herbert L Bonkovsky; Colin E Bishop
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

7.  Indole-3-Acetic Acid Alleviates Nonalcoholic Fatty Liver Disease in Mice via Attenuation of Hepatic Lipogenesis, and Oxidative and Inflammatory Stress.

Authors:  Yun Ji; Yuan Gao; Hong Chen; Yue Yin; Weizhen Zhang
Journal:  Nutrients       Date:  2019-09-03       Impact factor: 5.717

8.  Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver Disease in vivo: A Systematic Review.

Authors:  Faezah Sabirin; Siong Meng Lim; Chin Fen Neoh; Kalavathy Ramasamy
Journal:  Front Nutr       Date:  2022-04-11

9.  Evaluation of potential serum biomarkers of hepatic fibrosis and necroinflammatory activity in dogs with liver disease.

Authors:  Chantel Raghu; Joanne Ekena; John M Cullen; Craig B Webb; Lauren A Trepanier
Journal:  J Vet Intern Med       Date:  2018-02-27       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.